Page URL: https://www.bionews.org.uk/page_93113

$1.1 million more funding for multiple sclerosis trial in Bristol

8 August 2011
Appeared in BioNews 619

More than £600,000 has been donated to the Frenchay Hospital in Bristol for research into the use of stem cells as a treatment for multiple sclerosis (MS).

Bone marrow samples will be taken from the 80 selected MS patients, their stem cells extracted from it and then injected back into their bloodstream.

'When you inject these cells in to the bloodstream they do find their way into the brain and spinal cord', lead researcher Professor Neil Scolding told the BBC. 'We know once they get there they are capable of encouraging repair of damage in a variety of ways'.

The $1.1 million was given to the Burden Neurological Institute based at the hospital by American benefactor The Kenneth and Claudia Silverman Family Foundation.

Professor Scolding said: 'MS is the most common disabling neurological condition affecting young adults. Thanks to this generous donation... we are able to take a major step forward in our research to try and find a treatment for this disease'.

The Phase II trial, due to begin in late 2011, expands on the results of a pilot study that took place last year, which was reported in BioNews 557. The previous study found that nerve function increased by 20 percent after treatment and caused no serious adverse side effects. The disease remained stable in five of the six patients treated, and did not deteriorate over 12 months following the injection.

This work is unlike previous research in that these stem cells are not pre-treated to increase certain subsets of cells, and participants do not receive any immunosuppressant drugs prior to injection.

MS is caused by damage to the substance that protects nerve fibres in the central nervous system and affects around 100,000 people in the UK. Symptoms can include muscle weakness, dizziness, loss of balance, extreme fatigue, and visual and speech difficulties.

SOURCES & REFERENCES
$1.1 million donation for pioneering stem cell MS trial
North Bristol NHS Trust press release |  8 August 2011
MS stem cell trial at Burden Institute gets $1m grant
BBC News |  1 January 1970
MS stem cell trial in Bristol gets major grant
MS Trust press release |  1 January 1970
UK phase I stem cell study results published
MS Trust |  1 August 2011
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
19 September 2011 - by Antony Starza-Allen 
A new fund to help pay for stem cell research in Scotland has been launched. The UK Stem Cell Foundation (UKSF) will aim to raise £5 million over three years to support the work of researchers and clinicians in Scotland into treatments and cures for illnesses including diabetes, strokes, multiple sclerosis, blindness and Alzheimer's disease...
15 August 2011 - by Dr Rebecca Hill 
Researchers have identified 29 new genetic variants with a link to multiple sclerosis (MS). This brings the total number of genetic changes associated with the disease, which affects around 2.5 million people worldwide, to nearly 50...
1 August 2011 - by Dr Caroline Hirst 
UK scientists are launching a global clinical trial to test the potential and safety of stem cells to treat multiple sclerosis (MS)...
13 June 2011 - by Dr Sophie Pryor 
A naturally occurring protein can activate stem cells in mouse hearts, producing new muscle cells to replace the tissue damaged by a heart attack, UK scientists have found...
10 May 2010 - by Dr Rachael Panizzo 
A clinical trial investigating the treatment of patients with multiple sclerosis (MS) using bone marrow stem cells has produced encouraging results, researchers at Bristol University have reported....
1 October 2007 - by Katy Sinclair 
By Katy Sinclair: Tests taking place at the Frenchay Hospital near Bristol, UK, have raised hopes that stem cell injections could reverse the physical decline experienced by multiple sclerosis (MS) patients. The trial, led by Neil Scolding, professor of clinical neurosciences for North Bristol NHS Trust, involves injecting patients with...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.